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Introduction
Mesenchymal  progenitor  cells  (MPCs)  are  multipotent 
cells, derived from various adult tissues, that are capable of 
differentiating  into  several  mesenchymal  lineages, 
including  osteoblasts,  chondroblasts,  and  adipocytes.  A 
large  body  of  data  suggested  MPCs  as  a  promising 
candidate cell type applicable for repair and regeneration 
of a variety of mesenchymal tissues such as bone, carti  lage, 
and  muscle  [1,2].  MPCs  were  initially  identified  and 
isolated from bone marrow (BM) and are characterized by 
the expression of a number of cell surface markers [3‑5]. 
Based on their clonogenic and multipotent differen  tiation 
activities, to date, MPCs have been isolated from a number 
of  adult  tissues,  including  trabecular  bone  [6],  fat  [7,8], 
synovium  [9,10],  skin  [11],  thymus  [11,12],  periodontal 
ligament  [13],  as  well  as  prenatal  and  perinatal  sources 
such  as  umbilical  cord  blood  [14],  umbilical  cord  [15], 
palatine  tonsil  [16],  and  placenta  [17].  The  diversity  of 
sources  facilitates  MPC  accessibility,  but  also  raises 
questions  about  possible  phenotypic  and  functional 
discrepancies that must be addressed for their clinical use.
The transforming growth factor‑β (TGF‑β) superfamily 
of secreted factors includes TGF‑β, activins, Nodal, and 
bone morphogenetic proteins (BMPs). The activation of 
the  TGF‑β/activin/Nodal  signaling  pathway  through 
SMAD2/3 is associated with the pluripotency of human 
embryonic  stem  cells  (hESCs)  and  is  required  for  the 
maintenance of their undifferentiated state [18]. Through 
the  induction  of  Oct4,  Nanog,  Nodal,  Wnt3,  basic 
fibroblast growth factor (FGF‑2), and FGF‑8, Activin A 
was shown to be a key regulator for the “stemness” main‑
tenance of hESCs [19]. Activin A, like other members of 
the TGF‑β superfamily, has also been described to affect 
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The actions of activin A are determined by a balance of 
the levels of activin A and its inhibitor, follistatin (FS). FS 
is a natural antagonist that binds activin with high affinity 
and  neutralizes  its  biologic  activities  by  preventing 
activin interaction with its membrane receptors [23,24]. 
Activin ligands exist in three forms: homodimers of the 
βA  and  βB  protein  subunits  constitute  activin  A  and 
activin B, respectively, and a heterodimer of βA and βB 
protein  subunits  represents  activin  AB.  These  ligands 
signal by binding to specific serine/threonine kinase type II 
(ActRIIA and ActRIIB) receptors. In the adult, activin βA 
subunit mRNA is produced in BM [25] and, like TGF‑β 
[26] and BMPs, activin A is abundantly localized in bone 
matrix  [27,28].  BM‑derived  stromal  fibroblasts  were 
reported to be the major source of activin A and FS in the 
BM [29]. The role of activin A in bone metabolism has 
been evaluated in several studies. Although an inhibitory 
effect of activin A on osteoblastic differentiation in rat 
and murine osteoblasts was described [30,31], activin A 
was also shown to stimulate osteoblastogenesis in murine 
bone  marrow  cultures  and,  in  vivo,  promotes  bone 
formation  and  fracture  healing  in  rodents  [27‑29,32]. 
Interestingly, it was recently shown that the osteoblastic 
differentiation of MPCs induced by BMP‑2 involved an 
activin‑dominant microenvironment, whereas adipogenic 
differentiation of MPCs in the presence of dexa  metha  sone 
occurred in an FS‑dominant microenvironment [33]. In 
this study, the authors suggested that activin A inhibits 
adipogenesis  by  affecting  the  adipocyte  trans  crip  tional 
factor  in  favor  of  osteoblastic  differentiation  [33,34]. 
Activin βA also was detected in developing carti  lage and 
identified as another member of the TGF‑β superfamily 
involved in the induction of limb chondro  genesis [35,36]. 
Therefore, activin A is likely to have pleiotropic functions, 
including  an  essential  role  in  sustain  ing  hESC  pluri‑
potency, and to play a critical role during skeletogenesis.
In addition to the MPCs derived from BM, MPCs that 
show  multidifferentiation  potential  have  also  been 
isolated from various tissues. However, compared with 
BM‑MPCs, these MPCs of different tissue origins may 
have different cellular properties and therefore present 
differ  ential clinical applicability for regenerative medicine. 
It  is,  therefore,  desirable  to  identify  a  factor  that 
differentially  correlates  with  and  provides  a  functional 
characterization of the individual “stem cell” state of the 
MPCs  from  various  sources.  In  this  regard,  activin  A, 
which has been shown to play a role in regulating MPC 
properties, may be considered as a candidate factor and 
should  be  examined  for  its  expression  and  functional 
correlation with the activities of various MPCs. For this 
purpose,  we  have  undertaken  a  comparative  study  of 
MPCs  derived  from  four  different  tissue  sources, 
including BM, palatine tonsil (T), dental pulp (DP), and 
skeletal  muscle  (M).  In  line  with  the  current  state  of 
knowledge  of  the  biology  of  BM‑derived  MPCs,  we 
carried  out  direct  comparisons  of  the  phenotypic  and 
functional  properties  of  MPCs  isolated  from  these 
different sources. Specifically, we tested the hypothesis 
that activin A may function as a critical regulatory factor 
for MPCs multipotency. We further dissected the require‑
ment  of  activin  A  in  human  MPCs  induction  toward 
differentiation into chondrocytes, osteoblasts, and adipo‑
cytes. Our findings showed that activin A expression level 
in  MPCs  discriminates  MPCs  from  different  sources  in 
terms of proliferation capacity and differentiation poten‑
tial. In addition to a possible role in MPC identity, activin 
A also appears to play a pivotal role in the early stages of 
MPC  chondrogenesis  and  osteogenesis  while  inhibiting 
adipogenesis. Furthermore, our results show that among 
the four tissue sources compared, BM‑derived MPCs have 
the highest differen  tiation potency and represent the most 
desirable cell type for regenerative medicine.
Materials and methods
MPC isolation and culture
Tonsil-derived MPCs (T-MPCs)
With Institutional Review Board (IRB) approval (George 
Washington  University,  Washington,  DC),  tonsils  were 
obtained  after  informed  consent  from  patients  under‑
going tonsillectomy as a result of recurrent episodes of 
acute  tonsillitis.  The  tissue  was  minced,  digested,  and 
processed by direct plating, as described previously [16]. 
Expansion  medium  consisting  of  Dulbecco’s  modified 
Eagle’s medium (DMEM) (Invitrogen Corporation, Carls‑
bad, CA, USA) with 10% fetal bovine serum (FBS) from 
selected  lots  (HyClone)  and  antibiotics  (50  µg/ml 
streptomycin and 50 IU/ml penicillin; Invitrogen).
Bone marrow-derived MPCs (BM-MPCs)
Bone marrow (BM) was obtained after informed consent 
from  patients  (39  to  58  years  old)  undergoing  lower 
extremity  reconstructive  surgery  with  IRB  approval 
(University  of  Washington,  Seattle,  WA,  and  George 
Washington  University)  and  was  processed  by  direct 
plating, as described previously [37]. BM aspirates were 
plated overnight in T‑150 cm2 culture flasks in the same 
expansion medium as T‑MPCs, and adherent cells were 
obtained  similarly.  Both  T‑MPCs  and  BM‑MPCs  were 
culture‑expanded in expansion medium at 37°C and 5% 
CO2 by using T‑150 Triple Flasks (Nunc), and medium 
changes were done twice weekly.
Traumatized muscle-derived MPCs (M-MPCs)
Traumatically  injured  muscle  was  collected  with  IRB 
approval  from  the  Walter  Reed  Army  Medical  Center 
(WRAMC,  Washington,  DC).  Patients  considered  for 
inclusion in this study had been exposed to orthopedic 
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wounds, and informed consent was obtained from each 
patient before tissue collection. These patients arrived at 
WRAMC approximately 3‑7 days after injury, and tissue 
was collected during debridement and irrigation proce‑
dures.  The  tissue  was  dissected,  minced,  digested,  and 
plated as described previously [38,39]. The adherent cells 
were  cultured  in  the  same  expansion  medium  as 
T‑MPCs. For the first 3 days, the cells were washed with 
Hank’s Balanced Salt Solution (HBSS), and the medium 
was replaced. The cells were subcultured into new flasks 
after  tightly  packed  colony‑forming  units  (CFUs)  were 
observed, and the cells were cultured in basal expansion 
or  Growth  Medium  (GM:  DMEM  supplemented  with 
10% FBS and 1 unit/ml of antibiotics) from that point 
forward. Subsequent subcultures were performed when 
the cells were approximately 85% confluent.
Dental pulp-derived MPCs (DP-MPCs)
Tooth  sample  collection  and  the  growth  of  pulp  cells 
followed protocols described previously [40,41]. Extrac‑
tion  of  third  molars  from  healthy  patients  (aged  16–
26 years) in the Department of Oral Surgery conformed 
to a protocol (H‑29892) approved by the University of 
Maryland  Medical  School  IRB.  Pulp‑cell  cultures  were 
established  through  enzyme  digestion.  Minced  pulp 
tissues were digested in a solution of 3 mg/ml collagenase 
type I and 4 mg/ml dispase (Sigma) for 30–60 min at 
37°C.  Cell  suspensions  were  obtained  by  passing  the 
digested tissues through a 70‑μm cell strainer (Becton‑
Dickinson). Single‑cell suspensions (1 × 105 cells/flask) 
were  seeded  in  5  ×  10‑cm  culture  flasks  containing 
Eagle’s  minimum  essential  medium  alpha  modification 
(α‑MEM) supplemented with 20% FBS, 2 mmol/L l‑gluta‑
mine, 100 μmol/L l‑ascorbic acid‑2‑phosphate, 100 U/ml 
penicillin‑G,  100  μg/ml  streptomycin,  and  0.25  μg/ml 
fungizone (Gemini Bio‑Products) and maintained under 
5%  CO2  at  37°C.  Clonogenic  cells  were  grown  to  70% 
confluence, passaged at a 1:3 ratio, and cultured in the 
same expansion medium as T‑MPCs.
Cell-proliferation assay
Cell‑proliferation  assays  were  performed  by  using  the 
Cell Counting Kit‑8 (Dojindo, Kumamoto, Japan). Cells 
were plated in 96‑well plates at 1 × 104 cells per well and 
cultured in the basal growth medium. At the indicated 
time points, cell numbers in triplicate wells were measured 
spectrophotometrically as A450 values of reduced WST‑8 
(2‑(2‑methoxy‑4‑nitrophenyl)‑3‑(4‑nitro  phenyl)‑5‑(2,4 
disulfophenyl)‑2H‑tetrazolium, monosodium salt).
Flow cytometry
For flow cytometry, BM‑MPCs, T‑MPCs, DP‑MPCs, and 
M‑MPCs (>2 × 105 cells) were washed and resuspended 
in phosphate‑buffered saline (PBS) + 0.1% FBS (PF), con‑
tain  ing saturating concentrations (1:100 dilution) of the 
following  conjugated  mouse  IgG1,κ  anti‑human  mono‑
clonal antibodies (BD Biosciences): CD14‑PE, CD34‑PE, 
CD45‑FITC, CD73‑PE, CD90‑FITC, CD105‑PE for 1 h at 
4oC. Cell suspensions were washed twice and resus  pen‑
ded in PF for analysis on a flow cytometer (FACSCalibur, 
BD Biosciences) by using the CellQuest ProTM software 
(BD Biosciences).
In vitro differentiation
MPCs were induced to undergo adipogenic, osteogenic, 
and chondrogenic differentiation, as described previously 
[37].  For  adipogenic  differentiation,  cells  were  seeded 
into  six‑well  tissue‑culture  plates  at  a  density  of 
20,000 cells/cm2 and treated for 3 weeks with adipogenic 
medium,  consisting  of  DMEM  with  10%  FBS,  and 
supplemented  with  0.5  mmol/L  3‑isobutyl‑1‑methyl‑
xanthine (IBMX), 1 μg/ml insulin, and 1 μmol/L dexa‑
metha  sone  (all  from  Sigma).  For  osteogenic  differen‑
tiation, cells were seeded into six‑well plates (Corning) 
at a density of 20,000 cells/cm2, and treated for 3 weeks 
with  osteogenic  medium,  consisting  of  DMEM  with 
10% FBS, and supplemented with 10 mmol/L β‑glycerol‑
phosphate,  10  nmol/L  dexamethasone,  50  μg/ml 
ascorbic  acid‑2‑phosphate,  and  10  nmol/L  1,25  di‑
hydroxy  vitamin D3 (Biomol International L.P., Plymouth 
Meeting, PA). To induce chondrogenic differentiation, 
96‑microwell  poly  propylene  plates  (Nunc,  Roskilde, 
Denmark) were seeded with 300,000 cells per well, and 
cell pellets formed by centrifugation at 1,100 rpm for 6 
minutes. The pellet cultures were treated for 3 weeks 
with chondrogenic medium, consisting of high‑glucose 
DMEM supple  men  ted with 100 nmol/L dexamethasone, 
50 μg/ml ascorbic acid‑2‑phosphate, 100 μg/ml sodium 
pyruvate,  40  μg/ml  l‑proline,  10  ng/ml  recombinant 
human  transforming  growth  factor‑β3  (TGF‑β3;  R&D 
Systems, Minneapolis, MN), and 50 mg/ml ITS‑premix 
stock (BD Biosciences).
Histochemistry
Oil Red O Staining
Three‑week  adipogenic  cultures  of  MPCs  were  rinsed 
twice with PBS, fixed in 4% buffered paraformaldehyde, 
stained with Oil red O (Sigma) for 5 minutes at room 
temperature, and counterstained with Harris‑Hematoxy‑
lin Solution (Sigma), to visualize lipid droplets.
Alkaline phosphatase and alizarin red S staining
MPCs cultured for 3 weeks in osteogenic medium were 
fixed  in  4%  paraformaldehyde,  rinsed,  and  stained  for 
alkaline  phosphatase  with  Naphthol  AS‑BI  substrate 
(Sigma) for 30 minutes at 37ºC in the dark. Osteogenic 
cultures were also fixed with 60% isopropyl alcohol and 
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(Rowley) at pH 4.2 to detect mineralization.
Alcian blue and picrosirius red staining
Chondrogenic  cell  pellets  were  fixed  in  4%  buffered 
paraformaldehyde,  rinsed  with  PBS,  serially  dehydrated, 
paraffin  embedded,  and  sectioned  at  10‑μm  thickness. 
Sections were stained with Alcian blue (pH 1.0) to detect 
sulfated proteoglycans and with Picrosirius Red (0.1% wt/
vol in saturated picric acid) to visualize collagen deposi  tion.
Lymphocyte proliferative assay
Peripheral  blood  from  healthy  human  donors  was 
collected into heparinized containers (BD Biosciences), 
and peripheral blood mononuclear cells (PBMCs) were 
isolated  by  Ficoll‑Hypaque  density  gradient  centrifu  ga‑
tion.  Responder  human  PBMCs  were  resuspended  in 
RPMI  1640  medium  containing  10%  FBS,  2  mmol/L 
glutamine, 100 U/ml penicillin, and 100 µg/ml strepto‑
mycin, 0.1 mmol/L nonessential amino acids, 1 mmol/L 
sodium  pyruvate,  20  mmol/L  HEPES,  and  50  μmol/L 
2‑mercaptoethanol  (Invitrogen).  PBMCs  were  seeded  in 
triplicates at 1 × 105 cells/100 µl per well in 96‑well round‑
bottom plates (BD Biosciences). PHA was used at 5 μg/ml 
as a positive control mitogen to induce T‑cell proliferation. 
MPCs (5 × 104 cells) were added to obtain a final volume of 
300  µl.  After  3  days  of  incubation,  1  µCi/well  [3H]‑
thymidine (GE Healthcare) was added, and radioactivity 
incorporation over a 12‑hour period was determined by 
liquid  scintillation  counting.  All  experi  ments  were 
performed in triplicate and repeated at least twice.
Immunohistochemistry
Chondrogenic  cell  pellets  were  fixed  in  4%  buffered 
paraformaldehyde, rinsed with PBS, serially dehydrated, 
paraffin  embedded,  and  sectioned  at  10‑μm  thickness. 
Sections  were  digested  with  1  mg/ml  hyaluronidase 
(Sigma) or 20 μg/ml proteinase K (Roche Diagnostics) in 
10 mmol/L Tris‑HCl (pH 7.5) for 30 minutes at 37°C. The 
sections  were  then  incubated  overnight  at  room 
temperature  with  the  following  antibodies  in  Tris‑
buffered saline containing 0.1% bovine serum albumin: 
antibodies  to  aggrecan  and  collagen  type  II  (Develop‑
mental  Studies  Hybridoma  Bank),  and  antibodies  to 
fibronectin  (R&D).  Immunostaining  was  detected  by 
using  the  chromogenic  streptavidin‑peroxidase  Histo‑
stain SP Kit for DAB (Zymed Laboratories, San Francisco, 
CA),  and  imaged  by  using  an  inverted  microscope 
equipped with a color charge‑coupled device camera.
RNA isolation and real-time reverse transcription-
polymerase chain reaction (RT-PCR)
RNA  was  extracted  from  monolayer  cultures  of  BM‑
MPCs, T‑MPCs, DP‑MPCs and, M‑MPCs by using the 
RNeasy  Kit  (Qiagen).  Total  RNA  (1  μg)  was  reverse 
transcribed  by  using  the  Multiscribe  reverse 
transcriptase  (Applied  Biosystems).  Real‑time  PCR 
reactions were performed as previously described [42]. 
Gene‑specific  primers  (forward  and  reverse)  were 
designed based on GenBank cDNA sequences (primer 
sequences  available  on  request).  Specific  transcript 
levels were normalized by comparison with the house‑
keeping  gene,  glyceraldehyde‑3‑phosphate  dehydro  ge‑
nase (GAPDH).
Western blot
MPCs cultures were treated with activin A (10 ng/ml) 
for  48  hours,  and  homogenized  in  RIPA  lysis  buffer 
(Sigma) supplemented with protease and phosphatase 
inhibitors.  Extracted  proteins  were  separated  on  12% 
polyacrylamide gels and electroblotted. The blots were 
immunoprobed  for  GAPDH  and  Sox‑2  (Santa  Cruz, 
CA).  Appropriate  horseradish  peroxidase–conjugated 
secondary antibodies were used for detection.
Activin A quantification
Activin  A  in  culture  supernatants  was  quantified  by 
using a commercially available enzyme‑linked immuno‑
sorbent  assay  kit  (R&D  Systems)  according  to  the 
manufacturer’s protocol.
siRNA transfection
Small  interfering  RNA  (siRNA)  duplexes  designed 
against  human  inhibin,  beta  A  (activin  A,  activin  AB 
alpha  polypeptide),  and  the  negative  control  siRNA 
obtained  from  Ambion  (Applied  Biosystems/Ambion, 
Austin,  TX)  were  reconstituted  by  following  the 
manufacturer’s guidelines. siRNAs were transfected into 
BM‑MPCs  by  electroporation  with  a  total  of  750,000 
cells  in  300  µl  of  siPORT  electroporation  buffer 
containing  45  µl  of  22.5  µg  siRNA by  using  the  BTX 
ECM  830  Electro  Square  Porator  System  (Harvard 
Apparatus). In brief, the mixture was transferred to a 
2‑mm gap BTX electroporation cuvette, which was then 
placed  in  the  apparatus  and  exposed  to  two  identical 
square‑wave pulses (parameters: 1,075 V, 105‑µs pulse 
length,  5‑second  duration  between  pulses).  After 
electroporation,  the  cuvettes  were  incubated  for 
15 minutes at 37°C in a 5% CO2/95% air atmosphere. 
The  transfected  MPCs  were  then  maintained  for 
24  hours  in  culture  medium  under  5%  CO2  at  37°C 
before differen  tiation analyses.
Statistics
Data  from  the  proliferation,  RT‑PCR,  and  ELISA 
experiments  were  analyzed  statistically  by  using 
Student’s  t  test,  with  statistical  significance  set  at 
P < 0.05.
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Differential cell properties among mesenchymal 
progenitor cells from various tissue sources
Before examining the role of activin A, the four types of 
MPCs (BM, T, DP, and M) were first examined in terms 
of several key properties.
Cell surface-marker expression
To confirm that these MPCs express typical cell‑surface 
markers, we performed fluorescence activated cell sort‑
ing (FACS) analysis. It was revealed that all MPCs were 
negative  for  CD14,  CD34,  and  CD45  expression  and 
positive for CD73, CD90, and CD105 (Table 1).
T-MPCs have a higher proliferation rate than other MPCs
Analysis of cell density as a function of culture time (48, 
96, 144, or 240 hours) in growth medium revealed that 
among  the  four  different  MPC  populations  tested, 
T‑MPCs proliferated at a significantly higher rate than 
did MPCs derived from the other tissues (Figure 1c).
BM-MPCs display the strongest chondrogenic and adipogenic 
potency, whereas DP-MCPs exhibit the highest level of matrix 
mineralization
We  compared  the  differentiation  potential  of  MPCs 
derived  from  bone  marrow,  tonsil,  muscle,  and  dental 
pulp with the chondrogenic, osteogenic, and adipogenic 
lineages. Cultures of MPCs derived from the four tissues 
under chondrogenic conditions produced pellets with a 
similar morphology and a shiny surface that is charac‑
teristic  of  cartilaginous  pellets.  At  day  21  of  chondro‑
genesis,  alcian  blue  (AB)  and  picrosirius  histologic 
staining of the chondrogenic pellets derived from BM‑
MPCs, M‑MPCs, and DP‑MPCs all revealed the presence 
of a sulfated proteoglycan‑ and collagen‑rich extracellular 
matrix.  In  comparison,  in  T‑MPC  pellets,  the  matrix 
contained  considerably  less  sulfated  proteoglycans, 
where  as collagen staining was highly positive (Figure 2a). 
Immunohistochemistry  showed  that  all  MPC  pellets 
produced collagen type II (COL2) and aggrecan (AGN), 
although the staining intensities for both COL2 and AGN 
were  higher  in  BM‑MPCs  compared  with  those  of 
T‑MPCs, M‑MPCs, and DP‑MPCs (Figure 2a). Quanti  tative 
RT‑PCR analysis of day 21 cultures showed that, in response 
to  the  chondrogenic  culture  conditions  and  induction 
medium,  expression  of  COL2  was  upregulated  in  all 
cultures, with the highest level in BM‑MPCs (Figure 2d).
Although to a lesser extent for T‑MPCs, MPCs from 
the four tissue sources cultured for 21 days in osteogenic 
medium exhibited increased ALP activity and produced a 
mineralized matrix that stained positive with alizarin red, 
with the highest level of mineralization seen in DP‑MPCs 
cultures (Figure 2b). Under the same osteogenic condi‑
tions,  gene  expression  of  osteocalcin  (OC),  associated 
with  mature  osteoblasts,  was  significantly  increased 
compared with the undifferentiated cells at day zero (D0) 
(Figure 2e).
MPCs cultured in adipogenic medium formed charac‑
teristic  intracellular  lipid‑rich  vacuoles  that  stained 
positive with oil red O. Compared with BM‑MPCs, T‑
MPCs, and M‑MPCs, DP‑MPCs displayed a lesser ability 
to form lipid vacuoles (Figure 2c). MPCs derived from 
the different tissue sources under adipogenic induction 
also  upregulated  the  expression  of  peroxisome 
proliferator‑activated  receptor‑γ  (PPAR‑γ),  a  master 
regulator  of  adipogenesis,  as  well  as  lipoprotein  lipase 
(LPL) (Figure 2f). To summarize, the nonequivalence in 
differentiation  potency  of  the  MPCs  included  (a)  BM‑
MPCs  displayed  a  significantly  greater  chondrogenic 
potential; (b) DP‑MPCs presented a higher capacity for 
extracellular  matrix  mineralization;  and  (c)  T‑MPCs 
showed an inferior ability to differentiate into chondro‑
cytes and osteoblasts but a high adipogenic potential.
BM-MPCs exhibit greater immunosuppressive properties
In addition to their multilineage differentiation potential, 
MPCs  have  been  shown  to  display  immunoregulatory 
properties that have prompted consideration of their use 
in bone marrow transplantation [3,43,44]. Although the 
exact  immunosuppressive  mechanisms  of  MPCs  are 
unknown, the capacity of MPCs to suppress T‑cell proli‑
fera  tion stimulated by allogeneic lymphocytes, dendritic 
cells, and phytohemagglutinin (PHA) is well documented 
[45,46]. The immunosuppressive properties of the MPCs 
derived  from  different  tissue  sources  were  tested  in  a 
lymphocyte proliferative assay by using human peripheral 
blood mononuclear cells (PBMCs) from healthy donors 
and stimulated with PHA, a mitogen. The addition of BM‑
MPCs, T‑MPCs, M‑MPCs, and DP‑MPCs to the activated 
PBMCs inhibited the PHA‑induced prolifera  tive response 
of PBMCs (Figure 1d). The immuno  modulatory activity of 
Table 1. Surface epitope phenotype of bone marrow-, 
tonsil-, muscle-, and dental pulp-derived mesenchymal 
progenitor cells*
  BM-MPCs  T-MPCs  M-MPCs   DP-MPCs
CD14  –  _  _    _
CD34  _  _  _    _
CD45  _  _  _    _
CD73  +  +  +   +
CD90  +  +  +   +
CD105  +  +  +   +
*Surface epitopes or CD markers identified on the basis of immuoreactivity 
analyzed by fluorescence-activated cell sorting (FACS). FACS analysis showed 
that more than 95% of these cells were negative (-) for the expression of CD14, 
CD34, and CD45, and were positive (+) for CD73, CD90 and, CD105. Controls 
consisted of fluorescence observed with isotypic controls. BM, bone marrow; DP, 
dental pulp; M, muscle; MPC, mesenchymal progenitor cell; T, tonsil.
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of T‑MPCs, M‑MPCs, or DP‑MPCs (Figure 1d).
Involvement of activin A in the regulation of mesenchymal 
progenitor cell properties
Given  that  the  MPCs  from  the  various  tissue  sources 
exhibit differences in terms of cell proliferation, multi‑
potency,  and  immunomodulatory  properties,  we  next 
examined  the  involvement  of  activin  A  by  analyzing 
whether activin A (a) is expressed differentially in these 
MPC  populations,  (b)  regulates  MPC  differentiation 
potential, and (c) regulates Sox2 expression in the MPCs.
Activin A distinguishes mesenchymal progenitor cells from 
different tissue sources
ELISA was used to quantify activin A secretion in the 
supernatants  of  MPCs  derived  from  the  four  tissue 
sources. M‑MPCs and BM‑MPCs expressed the highest 
levels of activin A, whereas T‑MPCs had the lowest level 
(Figure 1a). Next, the activin A:FS ratio was determined, 
because  activin  A  bioactivity  is  also  regulated  by  FS. 
Quantitative  RT‑PCR  results  showed  that  the  activin 
A:FS level was also significantly lower in T‑MPCs than in 
the other MPCs tested (Figure 1b).
Activin A expression levels regulate mesenchymal progenitor-
cell differentiation potential
Because BM‑MPCs exhibited high activin A expression 
level as well as the highest chondrogenic potential among 
the MPCs tested, we next determined the role of activin A 
in  their  multipotency  by  silencing  of  activin  A  in 
BM‑MPCs. With the transfection protocol using 22.5 µg 
of  Cy3‑conjugated  control  siRNA,  a  transfection  effici‑
ency of 91.66 ± 1.36% at day 2 and of 57.36 ± 3.27% at day 
7 was achieved. BM‑MPCs were transfected with either 
activin A or control siRNA oligonucleotides. Analysis of 
culture supernatants demonstrated that activin A siRNA 
transfection  significantly  reduced  activin  A  level 
(0.81  ±  0.08  ng/ml)  compared  with  the  si  Control 
(2.32 ± 1.12 ng/ml) (Figure 3a). Twenty‑four hours after 
transfection  with  gene‑specific  designed  siRNA  against 
activin  A  or  with  the  Control  siRNA,  BM‑MPCs  were 
Figure 1. Activin A expression profile, proliferative rate, and immunosuppressive characteristics of MPCs from different tissue sources. 
(a) ELISA quantification of secreted activin A. Results are expressed as the mean of secretion in 48-hour supernatants of three cell cultures (mean 
± S.D.). (b) Activin A:follistatin ratio by real-time RT-PCR. (c) Cell-proliferation rate determined by using CCK-8. BM-MPCs, T-MPCs, M-MPCs, and 
DP-MPCs were plated in 96-well plates at 1 × 104 cells per well and cultured in growth medium for 48, 96, 144, and 240 hours. (d) Proliferative 
activity of T cells stimulated with PHA. Responding PBMCs were stimulated with PHA at 5 µg/ml in the presence or absence of 5 × 104 MPCs. The 
proliferative response of T cells is represented as a percentage of PHA control (mean ± SD of triplicates). *P ≤ 0.05, versus BM-MPCs; **P ≤ 0.05 
versus PHA.
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blastic and adipocytic lineages. On activin A knockdown, 
BM‑MPCs  displayed  decreased  chondro  genic  and 
osteo  genic potentials. By day 21, BM‑MPCs transduced 
with activin A siRNA, and induced to differentiate into 
chondrocytes, formed a pellet similar to the un  transfected 
Figure 2. In vitro-induced differentiation of MPCs from different tissue sources. (a-d) Chondrogenic differentiation evaluated after 21 days 
in micropellet culture. (a) Immunohistochemical analysis of cartilage markers (COL2 and AGN) and alcian blue (AB) and picrosirius (PS) staining in 
pellet cultures of MPCs. (d) Expression of COL2, a specific marker for chondrogenesis, measured in differentiated MPC cultures compared with day 0 
(D0) cultures, determined by quantitative RT-PCR with GAPDH as an internal control. (b-e) Osteogenic differentiation of MPCs assessed after 21-day 
culture in osteogenic medium. (b) All MPCs tested exhibited ALP activity and produced a mineralized matrix stained with alizarin red. T-MPCs 
displayed less alizarin red staining compared with BM-MPCs, M-MPCs, and DP-MPCs. (e) Significant upregulation of the expression of osteocalcin 
(OC), an osteoblast-specific gene, compared with undifferentiated MPCs was observed after osteogenic induction of BM-MPCs, T-MPCs, M-MPCs, 
and DP-MPCs compared with D0 cultures. (c-f) Adipogenic differentiation of MPCs cultured in adipogenic medium for 21 days. (c) All MPCs tested 
exhibited lipid-containing intracellular vacuoles that stained with oil red O at the end of the differentiation period. (f) MPCs cultured in adipogenic 
medium upregulated the expression of adipocyte-specific genes (PPAR-γ and LPL) compared with MPCs at D0. Quantitative RT-PCR data represent 
the mean ± SD in three independent experiments. *P ≤ 0.05, versus D0; **P ≤ 0.05, versus BM-MPCs.
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Histologic  staining  showed  a  clear  decrease  in  sulfated 
proteoglycan content and in fibrous collagen matrix, as 
assessed  by  alcian  blue  and  Picrosirius  red  staining, 
respectively (Figure 3b). This observation was supported 
by  the  decrease  in  COL2  mRNA  expres  sion  in  pellets 
formed with activin A siRNA transfected cells, as assessed 
by  quantitative  RT‑PCR  (Figure  3c).  BM‑MPCs  lacking 
activin  A  and  induced  to  undergo  osteogenesis  also 
displayed  decreased  mRNA‑expression  levels  of 
osteoblastic markers such as OC and ALP (Figure 3c).
Activin A knockdown also affected matrix mineraliza‑
tion in osteogenically induced BM‑MPCs compared with 
the untransfected cells (Figure 3b). Additionally, trans‑
fection  of  BM‑MPCs  with  activin  A  siRNA  enhanced 
their  differentiation  toward  the  adipocytic  lineage. 
Compared with BM‑MPCs transfected with the Control 
siRNA, activin A knockdown in BM‑MPCs significantly 
increased  the  expression  level  of  PPAR‑γ  and  LPL 
(0.01  ±  0.007  to  0.03  ±  0.01  and  0.004  ±  0.001  to 
0.08  ±  0.08,  respectively)  (Figure  3c).  In  summary,  the 
transient  knockdown  of  activin  A  in  BM‑MPCs  at  the 
Figure 3. Role of activin A in MPC multipotency. BM-MPCs transiently transfected either with control siRNA or with activin A siRNA were 
analyzed. (a) Activin A secretion level in the supernatant of transfected BM-MPCs quantified by ELISA 3 days (D3) after transfection showed 
the efficiency of knockdown by using activin A siRNA. (b, c) Effect of activin A knockdown on BM-MPC and T-MPC chondrogenic potential. 
Chondrogenic differentiation was evaluated after 21 days in micropellet culture. (b) Immunohistochemical analysis of cartilage markers (COL2 
and AGN) in pellet cultures of BM-MPCs and T-MPCs as well as alcian blue (AB) and picrosirius red (PS) staining revealed that, compared with the 
untransfected and Control siRNA, MPCs transfected with activin A siRNA exhibited less chondrogenic potential. (c) Quantitative RT-PCR also showed 
decreased expression of COL2 in MPCs transfected with activin A siRNA, compared with the cells transfected with control siRNA (c). (b, c) Effect 
of activin A knockdown on BM-MPC osteogenic potential. Both the expression levels of the osteogenic markers (OC and ALP), determined by 
quantitative RT-PCR, and alizarin red staining, revealed a decrease in the osteogenic activity of BM-MPCs with activin A knockdown. (b, c) Effect 
of activin A knockdown on BM-MPC adipogenic potential. Both expression levels of the adipogenic markers (PPAR-γ and LPL), determined by 
quantitative RT-PCR and oil red O staining, revealed an increase in the adipogenic potential of BM-MPCs with activin A knockdown, compared with 
BM-MPCs transfected with the irrelevant Control siRNA. RT-PCR data represent the mean ± SD of three independent experiments. *P ≤ 0.05, versus 
Control siRNA.
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Page 8 of 13early  stages  of  the  differentiation  process  appeared  to 
stimulate  adipogenesis  while  inhibiting  chondrogenesis 
and osteogenesis.
Activin A increases Sox2 expression in BM-mesenchymal 
progenitor cells
Sox2, a transcription factor highly expressed in undiffer‑
entiated ES cells, has been shown to stabilize ES cells in a 
pluripotent state [47,48]. With Western blot analysis, we 
observed  that  although  untreated  MPCs  expressed 
undetectable  or  low  levels  of  Sox2  protein,  its  level 
increased 48 hours after the treatment with 10 ng/ml of 
activin A (Figure 4a).
The  activin  A:follistatin  ratio  was  assessed  by  using 
quantitative RT‑PCR before and after the differentiation 
of  BM‑MPCs  into  chondrocytes,  osteoblasts,  and 
adipocytes. The activin A:follistatin ratio was significantly 
lower  in  all  differentiated  cells  compared  with 
undifferentiated  BM‑MPCs  (Figure  4b).  In  a  similar 
manner,  the  Sox2  mRNA  expression  level  was  also 
significantly  decreased  in  the  differentiated  cells 
compared with undifferentiated BM‑MPCs (Figure 4c).
Discussion
To realize the potential of MPCs in clinical applications, 
it is important to understand the biologic regulation of 
their multipotency. We attempted to gain insights into 
this by analyzing comparable MPCs derived from various 
tissue  sources  that  have  similar  but  non‑identical 
characteristics and biologic activities, and we observed a 
requirement for activin A expression in the maintenance 
of MPC identity, as well as the regulation of MPC func‑
tions. Moreover, our findings strongly suggest the high 
potency of bone marrow‑derived MPCs compared with 
MPCs from other tissue sources.
We  showed  that  MPCs  isolated  from  bone  marrow, 
tonsil, muscle, and dental pulp all display phenotypic and 
functional properties that currently characterize MPCs. 
However, significant differences in activin A expression 
levels  and,  more  important,  in  the  activin  A:follistatin 
ratios, which corroborate with MPC multipotency and 
immunosuppressive properties, were observed. Activins 
bind to the activin type IIA or type IIB receptors, leading 
to recruitment and phosphorylation of the activin type IB 
receptor,  which  in  turn  phosphorylates  intracellular 
Figure 4. Relation between Sox2 expression levels and activin A:follistatin expression ratio in MPCs from different tissue sources. 
(a) Western blot analysis of Sox2 expression in BM-MPCs, T-MPCs, M-MPCs, and DP-MPCs before and after a 48-hour treatment with 10 ng/ml of 
activin A. (b) Activin A:follistatin expression ratio determined by quantitative RT-PCR in BM-MPCs before (day 0 (0)) and after their differentiation 
along chondrogenic, osteogenic, and adipogenic lineages. (c) mRNA expression levels of Sox2 in undifferentiated (day 0 (0)) and chondro-, osteo- 
and adipo-differentiated BM-MPCs. The values at day 0 (0) corresponding to the mRNA ratio of activin A:follistatin (b) to the mRNA level of Sox2 (c) 
relative to GAPDH were assigned the values of 100% ± SD. *P ≤ 0.05, versus Day 0.
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Page 9 of 13signaling proteins, Smad2 or Smad3. Activin A signaling 
is inhibited by extracellular action of follistatin, a soluble 
protein  that  functions  as  an  activin‑binding  protein  to 
prevent activin from interacting with its receptor. Activin 
A but not the activin A:follistatin ratio was significantly 
higher  in  M‑MPCs  compared  with  the  other  MPCs 
tested.  In  T‑MPCs,  both  activin  A  level  and  activin 
A:follistatin ratio were significantly lower compared with 
the other MPCs. In parallel, we showed that the prolifera‑
tive rate of T‑MPCs was significantly higher compared 
with the other MPCs studied. This observation suggests 
that the endogenous high level of activin A might reduce 
the proliferation of BM‑MPCs, M‑MPCs, and DP‑MPCs 
compared with that of T‑MPCs. Although activin A is 
widely expressed by various cells, the effects of activin A 
are diverse, and cell type dependent. In general, activin A 
exerts  antiproliferative  effects  on  many  cell  types, 
including  epithelial  cells  and  vascular  endothelial  cells 
and  lymphocytes  [49,50].  However,  several  cell  types, 
including  fibroblast‑like  synoviocytes  (FLS)  and  lung 
fibro  blasts, proliferate in response to activin A [51,52]. In 
the  study  using  FLS,  the  authors  emphasized  the 
differences between the amount of activin A produced by 
the FLS (<1 ng/ml) and the amount of exogenous activin 
A necessary to promote FLS proliferation (250 ng/ml).
Besides cell growth, activin A has been widely studied 
for its role in cell differentiation. Several studies demon‑
strated  a  role  for  activins  in  bone  metabolism.  During 
differentiation and bone formation, osteoblasts produce a 
characteristic extracellular matrix that eventually under‑
goes  mineralization.  Although  activin  A  has  been 
described to promote osteoblastogenesis in murine bone 
marrow cultures and to enhance in vivo bone formation 
and fracture healing in rodents [27‑29,32], other reports 
described  an  inhibitory  effect  of  activin  on  osteoblast 
differentiation  in  rat  and  murine  osteoblasts  [30,31]. 
These  opposite  effects  of  activin  A  in  murine  rodent 
models might be explained by the cell type used (that is, 
activin  A  is  a  potent  regulator  of  osteogenesis  with  a 
positive effect on uncommitted progenitor cells and an 
inhibitory action on mature osteoblasts). This postulate is 
supported  by  the  finding  that  activin  A  signaling  in 
osteoblasts  is  tightly  controlled  in  a  differentiation‑
dependent manner [53]. Mineralizing osteoblast cultures 
showed  decreased  activin  A  production.  Activin  A 
signaling controls human osteoblast differentiation and 
function  and  inhibits  matrix  mineralization  through 
mechanisms  that  include  altered  extracellular  matrix 
composition and maturation. The expression of activin A 
in bone, taken together with its effect on mineralization 
in vitro, strongly suggests a biologically important role 
for  activin  A  in  human  osteoblast  differentiation  and 
bone  metabolism  [53].  In  this  work,  we  observed  that 
T‑MPCs,  with  lower  level  of  activin  A  expression 
compared  with  the  other  MPCs,  also  exhibit  lower 
osteogenic  potential,  as  shown  by  ALP  activity  and 
alizarin red staining. The involvement of activin A in the 
early  events  of  osteogenesis  is  also  supported  by  the 
effects  of  siRNA‑mediated  transient  knockdown  of 
activin  A  gene  expression  in  BM‑MPCs  induced  to 
under  go  osteogenesis.  Activin  A  knockdown  reduced 
both  the  expression  of  osteoblast‑specific  markers  and 
matrix mineralization at day 21. In addition, we showed 
that in BM‑MPCs under osteogenic induction, the activin 
A:follistatin ratio was significantly decreased at the end 
of  the  differentiation  period  compared  with  day  0.  An 
activin‑dominant microenvironment thus appears to be 
critical for the early stage of osteoblastic differentiation. 
Compared  with  BM‑MPCs,  M‑MPCs,  and  DP‑MPCs, 
T‑MPCs with the lowest activin A level also exhibit the 
lowest chondrogenic potential. In addition, we observed 
that  activin  A  knockdown  in  BM‑MPCs  significantly 
affects  their  chondrogenic  potential.  The  activin  A 
expression level in MPCs thus appears to govern both 
their chondrogenic and osteogenic potential. Our study 
is consistent with previous studies showing that during 
skeletal development, activin A is involved early at the 
beginning  of  the  cascade  of  events  promoting  mesen‑
chymal condensations and thus chondrogenic/osteogenic 
differentiation [54,55]. At the early phase of adipogenesis, 
activin  A  treatment  suppresses  differentiation,  which 
could  be  rescued  with  follistatin  [34].  This  inhibitory 
effect of activin A on adipogenesis of progenitor cells acts 
through  suppression  of  the  adipocyte  transcriptional 
factor  cascade  [33].  Our  results  show  that  activin  A 
knockdown in BM‑MPCs undergoing adipogenic induc‑
tion results in a significant increase in their adipogenic 
activity.  Taken  together,  these  observations  raise  the 
possibility that the activin A expression level in MPCs is a 
key determinant in their commitment to a specific mesen‑
chymal  lineage,  and  activin  signaling  and  activin  target 
genes might be crucial for controlling MPC multipotency.
Another functional characteristic of MPCs or mesen‑
chymal stem cells (MSCs) is their capacity to inhibit the 
proliferation  of  activated  T  cells  [45].  The  precise 
mechanisms underlying the immunosuppressive effect of 
MPCs/MSCs still remain to be clarified. The suppression 
of T‑cell proliferation stimulated by allogeneic lympho‑
cytes,  dendritic  cells, and  mitogens,  such  as  PHA  or 
concanavalin A, has been well documented (for review, 
see [3]). Although controversial results have been reported, 
more convergent data now suggest that MPCs/MSCs may 
act by suppressing the differentiation of mono  cytes into 
mature  dendritic  cells  (DC)  thus  impairing  the 
stimulation of T cells [46,56,57]. Interest  ingly, in addition 
to its defined role in embryogenesis and erythroid cell 
differentiation in bone marrow, activin A has been shown 
to exert antiinflammatory effects [58,59]. Activin A was 
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inflammatory or immune processes [60]. More recently, 
activin A has been described as a novel DC‑derived cyto‑
kine  that  potently  attenuates  CD40  ligand‑specific 
cytokine and chemokine production. Blocking autocrine 
activin‑A  signaling  in  DCs  by  using  its  antagonist, 
follistatin, enhanced production of DC cytokines (IL‑6, 
IL‑10,  IL‑12p70,  and  TNF‑α)  [61].  These  correlations 
between activin A and immunosuppression support our 
data showing that lower level of activin A produced by 
T‑MPCs, compared with other MPC types, corresponds 
to their significantly lower immunosuppressive potential. 
However,  M‑MPCs  and  DP‑MPCs,  with  an  activin 
A:follistatin ratio similar to that of BM‑MPCs, are also 
significantly  less  immunosuppressive  than  BM‑MPCs. 
This  might  be  explained  by  the  fact  that  whereas  DC 
maturation inhibition is certainly a mechanism by which 
MPCs display suppressive activity, it probably is not the 
main mechanism.
In  addition,  in  this  report,  we  show  that  (a)  MPCs 
express the embryonic transcription factor Sox2 at a very 
low level and that its expression is enhanced on treatment 
with 10 ng/ml of activin A; (b) M‑MPCs exhibit higher 
expression levels of both activin A and Sox2 compared 
with  BM‑MPCs,  T‑MPCs,  and  DP‑MPCs;  and  (c)  the 
down  regulation  of  the  activin  A:follistatin  ratio  in 
differentiated  BM‑MPCs  parallels  a  reduction  in  Sox2 
expression level. Recent findings with hESCs show that 
activin A induces the expression of Oct4, Nanog, Nodal, 
Wnt3, bFGF, and FGF8, and is necessary and sufficient 
for the maintenance of self‑renewal and pluripotency of 
hESCs  [19].  In  MSCs,  Oct4  knockdown  results  in 
markedly decreased levels of Nanog and Sox2 expression 
[62]. Together, these studies strongly suggest that activin 
A is a key regulator in the maintenance of pluripotency of 
stem  cells  acting  upstream  of  the  master  embryonic 
transcription factors Oct4, Nanog, and Sox2.
Conclusions
MPCs are defined by their ability to give rise to meso‑
dermal  cell  types.  Multipotency  in  cultured  MPCs 
derived from various tissues results from the integration 
of  multiple  signals  to  preserve  this  identity.  In 
demonstrating  a  requirement  of  activin  A,  we  have 
shown  a  novel  candidate  signaling  mechanism  for  the 
maintenance of multipotency of MPCs.
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